中国临床药理学杂志2011，Vol.27Issue(2)：86-88,3.
重组人血小板生成素与白介素-11治疗白血病化疗后血小板减少症的疗效比较
Comparison the efficacy of rhTPO with rhIL-11 in the treatment of chemotherapy induced thrombocytopenia in patients with leukemia
鲁惠敏 1鲁会卿 2王景昌2
作者信息
- 1. 河南省人民医院药学部,郑州450003
- 2. 中国人民解放军第三医院血液科,陕西,宝鸡721001
- 折叠
摘要
Abstract
Objective To evaluate the efficacy and safety of recombinant human thrombopoietin (rhTPO) compared with recombinant human interleukin 11 (rhIL - 11 ) in the treatment of chemotherapy induced thrombocytopenia in patients with leukemia.Methods Sixty -nine patients with leukemia were divided into trial and control groups randomly.Patients in trial group were given subcutaneously rhTPO and patients in control group were subcutaneously rhIL - 11.The peripheral platelet count was observed consecutively.Results The mean minimal and maxima platelet count in the trial group was significantly higher than in the control group.The time of platelet count less than 50 × 109 L-1 and needed to achieve a level to 70 × 109 L-1 and 100 × 109 L-1 in the trial group were significantly shorter than in the control group.Slight adverse reaction was observed in the trial group.Conclusion rhTPO is effective and safe in the trial group of chemotherapy induced thrombocytopenia in patients with leukemia and worth using in clinic.关键词
重组人血小板生成素/重组人白介素-11/血小板减少症/化疗分类
医药卫生引用本文复制引用
鲁惠敏,鲁会卿,王景昌..重组人血小板生成素与白介素-11治疗白血病化疗后血小板减少症的疗效比较[J].中国临床药理学杂志,2011,27(2):86-88,3.
